TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of the Use of Universal Glove and Gowning on Healthcare Associated Infection Rates and Antibiotic Resistant Bacteria
Brief Summary: This study will test if doctors, nurses and other people who take care of patients in hospitals wearing gloves and gown for all contact with patients in an intensive care unit (ICU) will:

* Decrease the chance of patients getting an infection while in the hospital
* Decrease the chance of patients picking up bacteria as a result of being in the hospital
* Decrease the time a patient spends in the ICU or in the hospital
* Increase the frequency of adverse events

The study will also look at whether making doctors, nurses and other people who take care of patients wear gloves and gown for all contact with patients will decrease the amount of time healthcare workers spend with patients.

This study will gather information by comparing what happens in ICUs that continue to do what they were doing before the study with what happens in ICUs that require healthcare workers to wear gloves and gown for all contact with patients.

This study will provide information that will help to make being in the hospital safer for all patients.


Options:
A: Arm Label: Intervention Arm; Type: N/A; Interventions: N/A | Arm Label: Non-intervention - Usual Standard of Care; Type: N/A; Interventions: N/A
B: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A
C: Arm Label: Active Screening; Type: OTHER; Interventions: Device: nucleic acid amplification of nasal swab; nasal swab culture | Arm Label: Passive Screening; Type: OTHER; Interventions: Other: Nasal swab culture | Intervention Type: DEVICE; Name: nucleic acid amplification of nasal swab; nasal swab culture; Assigned to Arm(s): Active Screening | Intervention Type: OTHER; Name: Nasal swab culture; Assigned to Arm(s): Passive Screening
D: Arm Label: White coat group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uniform group; Type: EXPERIMENTAL; Interventions: Other: Physician uniform | Intervention Type: OTHER; Name: Physician uniform; Assigned to Arm(s): Uniform group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU
Brief Summary: Heparin is commonly used for anticoagulation of the extracorporeal circuit during continuous renal replacement therapy (CRRT) but the optimal mode of delivery has not yet been validated. Our study will compare dilute heparin to a standard concentration of heparin. The investigators hypothesize that heparin delivered in a dilute solution will augment coating of the filter fibers with anticoagulants, decreasing clotting events and increasing filter life. By improving delivery of heparin to the filter and circuit, where clotting events can disrupt dialysis, less heparin would be required for the extra-corporeal circuit and thus less heparin would be delivered back to the patient with blood return from the machine. By exposing the patient to less heparin it is hypothesized that fewer bleeding events would occur, making the dialysis treatment safer. If more of the filter's fibers remain patent and the filter is functional for a longer period of time, the CRRT would also be more effective.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard dose of dialysis | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: High dose of dialysis | Intervention Type: DEVICE; Name: Standard dose of dialysis; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: High dose of dialysis; Assigned to Arm(s): 2
B: Arm Label: Femoral route; Type: EXPERIMENTAL; Interventions: Procedure: Femoral route for hemodialysis | Arm Label: Jugular route; Type: EXPERIMENTAL; Interventions: Procedure: Jugular route for hemodialysis | Intervention Type: PROCEDURE; Name: Femoral route for hemodialysis; Assigned to Arm(s): Femoral route | Intervention Type: PROCEDURE; Name: Jugular route for hemodialysis; Assigned to Arm(s): Jugular route
C: Arm Label: Dilute heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dilute unfractionated heparin | Arm Label: Standard concentrated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard concentration unfractionated heparin | Intervention Type: DRUG; Name: Dilute unfractionated heparin; Assigned to Arm(s): Dilute heparin | Intervention Type: DRUG; Name: Standard concentration unfractionated heparin; Assigned to Arm(s): Standard concentrated heparin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Continuous venvenous hemofiltration (CVVH) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous venovenous hemodialysis (CVVHD) | Intervention Type: DEVICE; Name: Continuous venvenous hemofiltration (CVVH); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Continuous venovenous hemodialysis (CVVHD); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU
Brief Summary: Heparin is commonly used for anticoagulation of the extracorporeal circuit during continuous renal replacement therapy (CRRT) but the optimal mode of delivery has not yet been validated. Our study will compare dilute heparin to a standard concentration of heparin. The investigators hypothesize that heparin delivered in a dilute solution will augment coating of the filter fibers with anticoagulants, decreasing clotting events and increasing filter life. By improving delivery of heparin to the filter and circuit, where clotting events can disrupt dialysis, less heparin would be required for the extra-corporeal circuit and thus less heparin would be delivered back to the patient with blood return from the machine. By exposing the patient to less heparin it is hypothesized that fewer bleeding events would occur, making the dialysis treatment safer. If more of the filter's fibers remain patent and the filter is functional for a longer period of time, the CRRT would also be more effective.


Options:
A: Arm Label: Dilute heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dilute unfractionated heparin | Arm Label: Standard concentrated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard concentration unfractionated heparin | Intervention Type: DRUG; Name: Dilute unfractionated heparin; Assigned to Arm(s): Dilute heparin | Intervention Type: DRUG; Name: Standard concentration unfractionated heparin; Assigned to Arm(s): Standard concentrated heparin
B: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
C: Arm Label: Standard Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Citrasate; Type: EXPERIMENTAL; Interventions: Drug: Citrasate | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Standard Anticoagulation | Intervention Type: DRUG; Name: Citrasate; Assigned to Arm(s): Citrasate
D: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Dilute Unfractionated Heparin and Standard Concentrated Unfractionated Heparin Protocols for Anticoagulation of the Extra-corporeal Circuit During Continuous Renal Replacement Therapy in the ICU
Brief Summary: Heparin is commonly used for anticoagulation of the extracorporeal circuit during continuous renal replacement therapy (CRRT) but the optimal mode of delivery has not yet been validated. Our study will compare dilute heparin to a standard concentration of heparin. The investigators hypothesize that heparin delivered in a dilute solution will augment coating of the filter fibers with anticoagulants, decreasing clotting events and increasing filter life. By improving delivery of heparin to the filter and circuit, where clotting events can disrupt dialysis, less heparin would be required for the extra-corporeal circuit and thus less heparin would be delivered back to the patient with blood return from the machine. By exposing the patient to less heparin it is hypothesized that fewer bleeding events would occur, making the dialysis treatment safer. If more of the filter's fibers remain patent and the filter is functional for a longer period of time, the CRRT would also be more effective.


Options:
A: Arm Label: RCA Group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation) | Arm Label: Heparin group; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin) | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation); Assigned to Arm(s): RCA Group | Intervention Type: DRUG; Name: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin); Assigned to Arm(s): Heparin group
B: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
C: Arm Label: M100; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticoagulation with nafamostat mesilate | Arm Label: HF1000; Type: EXPERIMENTAL; Interventions: Drug: Anticoagulation with nafamostat mesilate | Intervention Type: DRUG; Name: Anticoagulation with nafamostat mesilate; Assigned to Arm(s): HF1000, M100
D: Arm Label: Dilute heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dilute unfractionated heparin | Arm Label: Standard concentrated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard concentration unfractionated heparin | Intervention Type: DRUG; Name: Dilute unfractionated heparin; Assigned to Arm(s): Dilute heparin | Intervention Type: DRUG; Name: Standard concentration unfractionated heparin; Assigned to Arm(s): Standard concentrated heparin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Laser or Debrider Tonsillotomy Versus Monopolar Tonsillectomy in Obstructive Sleep Apnea; Inflammation as a Determinate of Outcome
Brief Summary: Tonsil surgery for children suffering from obstructive sleep apnea have significant post operative morbidity including pain and occasionally bleeding. This morbidity is partly caused by post surgical inflammation. This inflammatory process can be quantified using various proinflammatory cytokines.

the goal of this study is to objectively compare the inflammatory process after treatment of obstructive sleep apnea with different surgical approaches to the enlarged tonsils.


Options:
A: Arm Label: Adenotonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillectomy | Arm Label: Adenotonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Adenotonsillotomy | Intervention Type: PROCEDURE; Name: Adenotonsillectomy; Assigned to Arm(s): Adenotonsillectomy | Intervention Type: PROCEDURE; Name: Adenotonsillotomy; Assigned to Arm(s): Adenotonsillotomy
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy | Intervention Type: PROCEDURE; Name: Tonsillectomy; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): 1
C: Intervention Type: PROCEDURE; Name: (adeno)tonsillectomy; Assigned to Arm(s): N/A
D: Arm Label: Electrocautery tonsillectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Debrider tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Arm Label: Laser tonsillotomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy | Intervention Type: PROCEDURE; Name: Tonsillectomy, laser tonsillotomy, debrider tonsillotomy; Assigned to Arm(s): Debrider tonsillotomy, Electrocautery tonsillectomy, Laser tonsillotomy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunomodulatory Properties of Fresh Versus Stored Packed Red Blood Cells for Transfusion
Brief Summary: Packed red blood cell units destined for transfusion can be stored for up to 42 days prior to transfusion based on Food and Drug Administration (FDA) guidelines. Recent studies suggest that certain patients transfused with blood stored for longer duration have poorer outcomes than patients transfused fresher blood. The investigators' hypothesis is that the delivery of an immediate and substantial load of hemoglobin-associated iron from a stored unit of blood leads to changes that explain the differences in outcome between patients transfused old versus fresh blood. The investigators propose to test this hypothesis in humans by transfusing an individual's own blood, both fresh and after storage, and comparing levels of various outcome measures.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of 5 days or less storage age | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of conventional storage age | Intervention Type: OTHER; Name: RBC transfusion of 5 days or less storage age; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RBC transfusion of conventional storage age; Assigned to Arm(s): 2
B: Arm Label: Short storage; Type: EXPERIMENTAL; Interventions: Biological: Blood transfusion | Arm Label: Long storage arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Long storage arm, Short storage
C: Arm Label: Fresh not-leukocyte-reduced RBCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: Fresh RBCs leukocyte-reduced; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: RBCs with storage longer than 15 days; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Fresh RBCs leukocyte-reduced, Fresh not-leukocyte-reduced RBCs, RBCs with storage longer than 15 days
D: Arm Label: Fresh transfusion; Type: OTHER; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Arm Label: Old transfusion; Type: EXPERIMENTAL; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Intervention Type: PROCEDURE; Name: Fresh transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion | Intervention Type: PROCEDURE; Name: Old transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunomodulatory Properties of Fresh Versus Stored Packed Red Blood Cells for Transfusion
Brief Summary: Packed red blood cell units destined for transfusion can be stored for up to 42 days prior to transfusion based on Food and Drug Administration (FDA) guidelines. Recent studies suggest that certain patients transfused with blood stored for longer duration have poorer outcomes than patients transfused fresher blood. The investigators' hypothesis is that the delivery of an immediate and substantial load of hemoglobin-associated iron from a stored unit of blood leads to changes that explain the differences in outcome between patients transfused old versus fresh blood. The investigators propose to test this hypothesis in humans by transfusing an individual's own blood, both fresh and after storage, and comparing levels of various outcome measures.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of 5 days or less storage age | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of conventional storage age | Intervention Type: OTHER; Name: RBC transfusion of 5 days or less storage age; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RBC transfusion of conventional storage age; Assigned to Arm(s): 2
B: Arm Label: ARM A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Two packed red blood cells Transfusion | Arm Label: ARM B; Type: EXPERIMENTAL; Interventions: Drug: Single red blood packed cells Transfusion | Intervention Type: DRUG; Name: Single red blood packed cells Transfusion; Assigned to Arm(s): ARM B | Intervention Type: DRUG; Name: Two packed red blood cells Transfusion; Assigned to Arm(s): ARM A
C: Arm Label: Fresh transfusion; Type: OTHER; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Arm Label: Old transfusion; Type: EXPERIMENTAL; Interventions: Procedure: Fresh transfusion, Procedure: Old transfusion | Intervention Type: PROCEDURE; Name: Fresh transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion | Intervention Type: PROCEDURE; Name: Old transfusion; Assigned to Arm(s): Fresh transfusion, Old transfusion
D: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Arm B; Type: OTHER; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Arm B, Standard of care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Blind Pharmacodynamic Study to Assess the Phosphate Binding Characteristics of K2CG Chewing Gum
Brief Summary: The specific purpose of this study is to describe the characteristics of the K2CG chewing gum, specifically as it relates to duration of gum chewing (exposure), timing of gum chewing in relation to a meal, and dose of K2CG chewing gum.


Options:
A: Arm Label: Chewing Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Arm Label: Chewing Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Other: K2CG chewing gum | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4 | Intervention Type: OTHER; Name: K2CG chewing gum; Assigned to Arm(s): Chewing Arm 1, Chewing Arm 2, Chewing Arm 3, Chewing Arm 4
B: Arm Label: ASP1585 dose #1; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #2; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #3; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sevelamer hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer hydrochloride | Intervention Type: DRUG; Name: ASP1585; Assigned to Arm(s): ASP1585 dose #1, ASP1585 dose #2, ASP1585 dose #3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): Sevelamer hydrochloride
C: Arm Label: Ferric Citrate; Type: EXPERIMENTAL; Interventions: Drug: Ferric Citrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ferric Citrate; Assigned to Arm(s): Ferric Citrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Sevelamer HCl; Type: EXPERIMENTAL; Interventions: Drug: Sevelamer HCl | Arm Label: Calcium-based binder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium-based phosphate binder | Intervention Type: DRUG; Name: Sevelamer HCl; Assigned to Arm(s): Sevelamer HCl | Intervention Type: DRUG; Name: Calcium-based phosphate binder; Assigned to Arm(s): Calcium-based binder

Answer: A